Biotech | May 16, 2022
Antengene announces commercial availability of Xpovio in China
The drug will be available in 600 hospitals and 105 DTPs
The drug will be available in 600 hospitals and 105 DTPs
It is developing the drug candidate to potentially treat immunological diseases
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Subscribe To Our Newsletter & Stay Updated
